Fulcrum Therapeutics Q1 2026 Earnings Narrowed Loss Exceeds Analyst Expectations BCDA Q1 2026 Earnings EPS Misses Estimates as No Revenue Reported Stock Edges Higher MLYS Q1 2026 Earnings Narrow Beat on Losses as Clinical Pipeline Progress Continues TRVI Q1 2026 Earnings WiderthanExpected Loss Amid PreRevenue Development Stage Trane Technologies Q1 2026 Earnings EPS Beats Estimates Amid Strong Operational Performance SWIM Q1 2026 Earnings Loss Narrower Than Expected as Cost Controls Take Hold